Abstract
Haematopoietic stem cells (HSCs) in mouse bone marrow are located in specialized niches as single cells. During homeostasis, signals from this environment keep some HSCs dormant, which preserves long-term self-renewal potential, while other HSCs actively self renew to maintain haematopoiesis. In response to haematopoietic stress, dormant HSCs become activated and rapidly replenish the haematopoietic system. Interestingly, three factors — granulocyte colony-stimulating factor, interferon-α and arsenic trioxide — have been shown to efficiently activate dormant stem cells and thereby could break their resistance to anti-proliferative chemotherapeutics. Thus, we propose that two-step strategies could target resistant leukaemic stem cells by priming tumours with activators of dormancy followed by chemotherapy or targeted therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dzierzak, E. & Speck, N. A. Of lineage and legacy: the development of mammalian hematopoietic stem cells. Nature Immunol. 9, 129–136 (2008).
Yoshimoto, M. & Yoder, M. C. Developmental biology: birth of the blood cell. Nature 457, 801–803 (2009).
Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nature Rev. Immunol. 6, 93–106 (2006).
Arai, F. et al. Niche regulation of hematopoietic stem cells in the endosteum. Ann. NY Acad. Sci. 1176, 36–46 (2009).
Kiel, M. J. & Morrison, S. J. Uncertainty in the niches that maintain haematopoietic stem cells. Nature Rev. Immunol. 8, 290–301 (2008).
Essers, M. A. et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 458, 904–908 (2009).
Wilson, A. et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118–1129 (2008).
Jorgensen, H. G. et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 12, 626–633 (2006).
Osawa, M., Hanada, K., Hamada, H. & Nakauchi, H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273, 242–245 (1996).
Dykstra, B. et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 1, 218–229 (2007).
Camargo, F. D., Chambers, S. M., Drew, E., McNagny, K. M. & Goodell, M. A. Hematopoietic stem cells do not engraft with absolute efficiencies. Blood 107, 501–507 (2006).
Ema, H. et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev. Cell 8, 907–914 (2005).
Kiel, M. J., Yilmaz, O. H., Iwashita, T., Terhorst, C. & Morrison, S. J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109–1121 (2005).
Morrison, S. J. & Weissman, I. L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1, 661–673 (1994).
Cheshier, S. H., Morrison, S. J., Liao, X. & Weissman, I. L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc. Natl Acad. Sci. USA 96, 3120–3125 (1999).
Yamazaki, S. et al. TGF-β as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250–1256 (2009).
Passegue, E., Wagers, A. J., Giuriato, S., Anderson, W. C. & Weissman, I. L. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599–1611 (2005).
Yoshihara, H. et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1, 685–697 (2007).
Foudi, A. et al. Analysis of histone 2B–GFP retention reveals slowly cycling hematopoietic stem cells. Nature Biotechnol. 27, 84–90 (2009).
van der Wath, R. C., Wilson, A., Laurenti, E., Trumpp, A. & Lio, P. Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine label-retaining cell dynamics. PLoS ONE 4, e6972 (2009).
Cheshier, S. H., Prohaska, S. S. & Weissman, I. L. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. 16, 707–717 (2007).
Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836–841 (2003).
Wilson, A. et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 18, 2747–2763 (2004).
Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149–161 (2004).
Lo Celso, C. et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457, 92–96 (2009).
Xie, Y. et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457, 97–101 (2009).
Arai, F. & Suda, T. Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann. NY Acad. Sci. 1106, 41–53 (2007).
Lane, S. W., Scadden, D. T. & Gilliland, D. G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114, 1150–1157 (2009).
Hooper, A. T. et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 4, 263–274 (2009).
Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625–637 (2002).
Bhattacharya, D. et al. Niche recycling through division-independent egress of hematopoietic stem cells. J. Exp. Med. 206, 2837–2850 (2009).
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nature Med. 12, 446–451 (2006).
Jang, Y. Y. & Sharkis, S. J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110, 3056–3063 (2007).
Kaushansky, K. The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 115, 3339–3347 (2005).
Bowie, M. B. et al. Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J. Clin. Invest. 116, 2808–2816 (2006).
Kim, I., He, S., Yilmaz, O. H., Kiel, M. J. & Morrison, S. J. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood 108, 737–744 (2006).
Bowie, M. B. et al. Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. Proc. Natl Acad. Sci. USA 104, 5878–5882 (2007).
Kim, I., Saunders, T. L. & Morrison, S. J. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 130, 470–483 (2007).
Morrison, S. J., Wright, D. E. & Weissman, I. L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc. Natl Acad. Sci. USA 94, 1908–1913 (1997).
Broxmeyer, H. E. Chemokines in hematopoiesis. Curr. Opin. Hematol. 15, 49–58 (2008).
Petit, I. et al. G.-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunol. 3, 687–694 (2002).
Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nature Rev. Drug Discov. 6, 975–990 (2007).
Jonasch, E. & Haluska, F. G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34–55 (2001).
de Veer, M. J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69, 912–920 (2001).
Holmes, C. & Stanford, W. L. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 25, 1339–1347 (2007).
Ito, C. Y., Li, C. Y., Bernstein, A., Dick, J. E. & Stanford, W. L. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 101, 517–23 (2003).
Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427–1429 (1995).
Radtke, F. et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10, 547–558 (1999).
Gothert, J. R. et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood 105, 2724–2732 (2005).
Sato, T. et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nature Med. 15, 696–700 (2009).
Venezia, T. A. et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2, e301 (2004).
Feng, C. G., Weksberg, D. C., Taylor, G. A., Sher, A. & Goodell, M. A. The p47 GTPase Lrg-47 (Irgm1) links host defense and hematopoietic stem cell proliferation. Cell Stem Cell 2, 83–89 (2008).
George, C. X., Das, S. & Samuel, C. E. Organization of the mouse RNA-specific adenosine deaminase Adar1 gene 5′-region and demonstration of STAT1-independent, STAT2-dependent transcriptional activation by interferon. Virology 380, 338–343 (2008).
George, C. X. & Samuel, C. E. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc. Natl Acad. Sci. USA 96, 4621–4626 (1999).
George, C. X., Wagner, M. V. & Samuel, C. E. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J. Biol. Chem. 280, 15020–15028 (2005).
Hartner, J. C., Walkley, C. R., Lu, J. & Orkin, S. H. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nature Immunol. 10, 109–115 (2009).
Wilson, A., Laurenti, E. & Trumpp, A. Balancing dormant and self-renewing hematopoietic stem cells. Curr. Opin. Genet. Dev. 19, 461–468 (2009).
Orford, K. W. & Scadden, D. T. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nature Rev. Genet. 9, 115–128 (2008).
Goldman, J. M. et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 23, 1708–1715 (2009).
Cortes, J., O'Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204–2205 (2004).
Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041–6051 (2009).
Roeder, I. et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Med. 12, 1181–1184 (2006).
Foo, J., Drummond, M. W., Clarkson, B., Holyoake, T. & Michor, F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput. Biol. 5, e1000503 (2009).
Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008).
Nasr, R. et al. Eradication of acute promyelocytic leukemia-initiating cells through PML–RARA degradation. Nature Med. 14, 1333–1342 (2008).
Nasr, R., Lallemand-Breitenbach, V., Zhu, J., Guillemin, M. C. & de The, H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 15, 6321–6326 (2009).
Drummond, M. W. et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23, 1199–1201 (2009).
Kujawski, L. A. & Talpaz, M. The role of interferon-α in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18, 459–471 (2007).
Hochhaus, A. First-line management of CML: a state of the art review. J. Natl Compr. Canc. Netw. 6, S1–S10 (2008).
Johansson, M., Denardo, D. G. & Coussens, L. M. Polarized immune responses differentially regulate cancer development. Immunol. Rev. 222, 145–154 (2008).
Adams, G. B. et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439, 599–603 (2006).
Ogawa, M. et al. CD34 expression by murine hematopoietic stem cells. Developmental changes and kinetic alterations. Ann. NY Acad. Sci. 938, 139–145 (2001).
Randall, T. D., Lund, F. E., Howard, M. C. & Weissman, I. L. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. Blood 87, 4057–4067 (1996).
Chen, C. Z. et al. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc. Natl Acad. Sci. USA 99, 15468–15473 (2002).
Chen, C. Z., Li, L., Li, M. & Lodish, H. F. The endoglinpositive sca-1positive rhodaminelow phenotype defines a near-homogeneous population of long-term repopulating hematopoietic stem cells. Immunity 19, 525–533 (2003).
Okada, S. et al. In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood 80, 3044–3050 (1992).
Balazs, A. B., Fabian, A. J., Esmon, C. T. & Mulligan, R. C. Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. Blood 107, 2317–2321 (2006).
Kent, D. G. et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 113, 6342–6350 (2009).
Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977–988 (2006).
Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Purification and characterization of mouse hematopoietic stem cells. Science 241, 58–62 (1988).
Acknowledgements
This work was supported in part by grants awarded to A.T. from the European Union 7th Framework Programme 'EuroSyStem' and the BioRN Spitzencluster 'Molecular and Cell Based Medicine' funded by the German 'Bundesministerium für Bildung und Forschung' (BMBF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- 5-Fluorouracil
-
(5-FU). A pyrimidine analogue, which is used as a drug in the treatment of cancer. It belongs to the familiy of drugs called anti-metabolites and mainly functions as a thymidylate synthase inhibitor. One of its main side effects is myelosuppression, shown by a massive loss of bone marrow and peripheral haematopoietic cells in 5-FU treated mice. This induces a feedback loop that activates previously dormant and therefore resistant HSCs to proliferate and self renew.
- Bromodeoxyuridine
-
(BrdU). A thymidine analogue that is incorporated into DNA during DNA replication. In vivo or in vitro treatment with BrdU can allow the detection of dividing cells by intracellular staining with fluorescence-labelled BrdU-specific antibodies followed by flow cytometry.
- Chronic myeloid leukaemia
-
(CML). A cancer of the white blood cells. This form of leukaemia is a clonal bone marrow stem cell disorder, which is characterized by the proliferation of mature granulocytes and their precursors in the bone marrow, followed by accumulation of these cells in the blood. CML is associated with a characteristic chromosomal translocation, the Philadelphia chromosome, generating an aberrant constitutively active tyrosine kinase called BCR–ABL. Treatment with the tyrosine kinase inhibitor imatinib mesylate has dramatically improved the survival of patients with CML over the past decade.
- Competitive-repopulation assay
-
A functional assay for measuring the activity of mouse HSCs. The HSC content of an undefined population of cells is determined by mixing the cells with a defined number of fresh bone marrow cells from another source. After transplantation into lethally irradiated mice, genetic markers are used to distinguish progeny from the two HSC sources in blood and haematopoietic organs. These measurements allow the assessment of HSC activity.
- Imatinib mesylate
-
(Gleevec/Glivec; Novartis). A tyrosine kinase inhibitor used to treat CML, gastrointestinal stromal tumours and other cancers caused by constitutively active tyrosine kinases, including BCR–ABL and KIT. In CML, imatinib mesylate binds to the site of tyrosine kinase activity of the fusion protein BCR–ABL and therefore prevents its activity.
- Mx1–Cre allele
-
An allele expressed in Mx1–Cre transgenic mice, in which the type I IFN-inducible Mx1 promoter controls expression of the Cre recombinase. By injection of polyinosinic–polycytidylic acid (polyI:C), type I IFNs are produced, which induces Cre recombinase expression. This induces highly efficient excision of loxP-flanked genes in HSCs and other blood cells, as well as hepatocytes.
- Side population
-
The ability of a cell to efflux the Hoechst 33342 dye by a multi-drug resistant-like transporter expressed on the cell surface. This can be measured by flow cytometry and used to enrich for murine HSCs.
Rights and permissions
About this article
Cite this article
Trumpp, A., Essers, M. & Wilson, A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10, 201–209 (2010). https://doi.org/10.1038/nri2726
Issue Date:
DOI: https://doi.org/10.1038/nri2726
This article is cited by
-
Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells
Nature Communications (2023)
-
Ferroptosis-inducing inorganic arsenic(II) sulfide nanocrystals enhance immune activation
Nano Research (2023)
-
Understanding Hematopoietic Stem Cell Dynamics—Insights from Mathematical Modelling
Current Stem Cell Reports (2023)
-
Modeling cancer’s ecological and evolutionary dynamics
Medical Oncology (2023)
-
Differentiation Kinetics of Hematopoietic Stem and Progenitor Cells In Vivo Are Not Affected by β-Glucan Treatment in Trained Immunity
Inflammation (2023)